Skip to main content
These products are not intended to diagnose, treat, cure, or prevent any disease. Research compounds are sold for laboratory and educational purposes only.
These products are not intended to diagnose, treat, cure, or prevent any disease. Research compounds are sold for laboratory and educational purposes only.
Nasal - KPV / Thymosin Alpha-1 – 10mg / 10mg

Nasal – KPV / Thymosin Alpha-1 – 10mg / 10mg

$225.00

466 in stock

466 in stock

  • Name:
    Thymosin Alpha-1 (TA-1) / KPV (Lys–Pro–Val) Combination (Immunomodulatory Thymic Peptide + Anti-inflammatory α-MSH Fragment Complex)
  • Sequence:
    TA-1 Sequence: Ac–Ser–Asp–Ala–Ala–Val–Asp–Thr–Ser–Ser–Glu–Ile–Thr–Thr–Lys–Asp–Leu–Lys–Glu–Lys–Lys–Glu–Val–Val–Glu–Glu–Ala–Glu–Asn–NH₂
    KPV Sequence: Lys–Pro–Val
  • Molecular Formula:
    TA-1 Molecular Formula: C₁₂₉H₂₁₅N₃₃O₅₅
    KPV Molecular Formula: C₁₆H₂₉N₅O₄
  • Molecular Weight:
    TA-1 Molecular Weight: ≈ 3108.3 g/mol
    KPV Molecular Weight: ≈ 355.4 g/mol
  • CAS Registry Number:
    TA-1 (14636-12-5)
    KPV (27219-07-2)

TA-1 / KPV – COMPREHENSIVE IMMUNOMODULATORY AND ANTI-INFLAMMATORY PEPTIDE COMPLEX FOR ADVANCED BIOLOGICAL RESEARCH

Scientific Overview of TA-1 / KPV

This dual-pathway peptide formulation combines Thymosin Alpha-1 (TA-1)—a biologically active thymic peptide known for its immune-enhancing and regulatory effects—with KPV, a tripeptide fragment of α-Melanocyte Stimulating Hormone (α-MSH) recognized for its potent anti-inflammatory properties.

Together, these peptides form a unique research complex aimed at exploring immune homeostasis, inflammation modulation, and tissue recovery through complementary mechanisms involving T-cell regulation and cytokine balance.

Thymosin Alpha-1 (TA-1)

TA-1 is a 28-amino acid peptide derived from thymic tissue, acting primarily through Toll-like receptors (TLR2 and TLR9) and downstream NF-κB signaling pathways.

Key research areas include:

• Immunomodulation and T-cell Activation – studies examining TA-1’s enhancement of dendritic cell maturation and T-lymphocyte response.
• Host Defense and Cytokine Regulation – investigation of TA-1’s balancing effect on pro- and anti-inflammatory cytokine networks.
• Viral and Immune Resilience Models – evaluation of TA-1 in innate and adaptive immune coordination research.

KPV (Lys–Pro–Val)

KPV, the C-terminal tripeptide of α-MSH, is a compact anti-inflammatory research molecule acting on melanocortin receptor 1 (MC1R) and inhibiting NF-κB activation.
Primary research applications:

• Inflammatory Response Modulation – exploration of cytokine suppression (IL-1β, TNF-α) in epithelial and immune tissues.
• Barrier Integrity and Wound Healing – assessment of peptide-driven epithelial recovery and cell signaling under stress conditions.
• Neuroimmune Interface Studies – examination of peripheral peptide–receptor crosstalk and immune cell signaling modulation.

Combined Research Applications

In combined peptide models, TA-1 and KPV provide a synergistic platform for:

• Studying immune system regulation and recovery under inflammatory or stress-induced conditions.
• Investigating the convergence of thymic and melanocortin signaling pathways in cytokine balance and tissue protection.
• Exploring immuno-inflammatory resilience through complementary modulation of innate and adaptive immune cascades.

This peptide combination offers a comprehensive dual mechanism for research into immune regulation, inflammation resolution, and tissue homeostasis—a modern model for integrative immunopeptide signaling studies.

COAs

COA_Nasal_TK1010N1125

*This peptide is intended solely for laboratory research use. It is not approved for human consumption or therapeutic application.

Skip to content